Back to dashboard
Episode 23
DIP Episode 23 - Comprehensive 3rd Year Psychiatry Shelf Review
PharmacologyMedium4 - HighHas Q&A
Step 2Step 3MedicineUSMLEStep 2Step 3
Topic
Schizophrenia diagnosis and symptoms; Antipsychotic pharmacology (MOA, side effects); Personality disorder differentiation; Bipolar spectrum disorders.
Key Takeaway
Mastering the temporal relationship between psychotic symptoms is critical for differentiating schizophrenia from schizotypal or schizoaffective disorders, while remembering that atypical antipsychotics are generally preferred first-line agents due to lower risks of extrapyramidal side effects (EPS).
Runtime: — min
Published: 2018-04-25
Completed audio: Yes
Completed notes: Yes
Anki made: Yes
Section: PSYCH
Episode Notes
Source / episode info
- Episode: 23
- Title: Divine Intervention Episode 23 – Comprehensive 3rd Year Psychiatry Shelf Review.
- Published: 2018-04-25
- Source: Episode page
One-liner
This review emphasizes the differential diagnosis of psychosis based on symptom duration and clusters, details the pharmacology and specific adverse effect profiles of various antipsychotics, and differentiates key personality disorders.
High-yield summary
- Schizophrenia Diagnosis: Requires symptoms (delusions, hallucinations, disorganized speech/behavior, negative symptoms) for a minimum of 6 months, with at least two of five core symptoms present.
- Antipsychotic Choice: Atypical neuroleptics are generally preferred over typical ones (e.g., Haloperidol) due to reduced risk of EPS.
- Drug Safety Pearls:
- Clozapine: The only antipsychotic proven to decrease the risk of suicide in schizophrenia; associated with agranulocytosis.
- Risperidone: Highest association with hyperprolactinemia (due to tuberoinfundibular pathway blockade).
- Olanzapine: Strongest association with metabolic syndrome (weight gain, elevated HbA1c, dyslipidemia).
- Ziprasidone: Strongest association with QT interval prolongation.
- Timeframe Differentiation: Schizophreniform Disorder (< 6 months); Brief Psychotic Disorder (< 1 month).
Learning objectives
- Differentiate the diagnostic criteria for various psychotic disorders based on symptom duration and clusters.
- Select appropriate antipsychotic agents while considering specific adverse effect profiles (e.g., hyperprolactinemia, metabolic syndrome).
- Recognize and manage acute extrapyramidal symptoms (EPS) such as dystonia, akathisia, and tardive dyskinesia.
- Differentiate between ego-dystonic (OCD) and ego-syntonic (OCPD) presentations of obsessive-compulsive traits.
- Apply knowledge of mood disorder severity to distinguish Bipolar I vs. Bipolar II episodes.
Board exam buzzwords
| Condition | Key Finding | Association | Board Exam Tip |
| Schizophrenia | Positive/Negative Symptoms | DA imbalance (Mesolimbic excess, Mesocortical deficit) | Remember that atypical antipsychotics help the mesocortical pathway by blocking 5 HT receptors. |
| Tardive Dyskinesia (TD) | Rapid, rhythmic tongue movements | High-potency typical antipsychotic use | The best management is to switch to an atypical agent or Clozapine; it is irreversible if left untreated. |
| Hyperprolactinemia | Gynecomastia, amenorrhea | Risperidone blockade of D2 receptors in the tuberoinfundibular pathway | This is a classic association for this specific drug. |
| Olanzapine | Weight gain/Metabolic Syndrome | High lipophilicity and strong antagonism across multiple receptors | Always screen patients starting antipsychotics for metabolic changes (HbA1c, lipids). |
Rapid review table
| Topic | Key Point | Context | Exam Relevance |
| Schizophrenia | Positive vs. Negative Symptoms | Delusions/Hallucinations (+) vs. Flat affect/Avolition (-) | Questions often list symptoms; knowing which are positive and which are negative is essential for diagnosis. |
| Antipsychotics | Atypical MOA | 5-HT2 A antagonism increases DA release in the mesocortical pathway. | Understanding this mechanism explains why atypicals treat both positive and negative symptoms better than typicals. |
| Bipolar Disorder | Manic vs. Hypomanic Episodes | Mania requires significant impairment; hypomania does not (DIGFAST lite). | The severity of functional decline dictates the diagnosis (BPD I vs BPD II). |
| Personality Disorders | OCPD vs. OCD | OCPD is ego-syntonic (feels right); OCD is ego-dystonic (knows it's irrational). | This distinction is a common test trap; the patient must recognize the abnormality. |
Board-speak -> diagnosis
| Board-speak / Vignette phrase | Diagnosis / Concept | Why it fits |
| Fixed, false beliefs despite evidence to the contrary (delusions) and hearing voices. | Schizophrenia/Psychosis | These are classic positive symptoms requiring careful temporal assessment for diagnosis. |
| Patient develops repetitive "circular" motions of the forearm shortly after starting an antipsychotic. | Acute Dystonia | This is a common, acute movement disorder caused by neuroleptic agents; often treated with anticholinergics (e.g., benztropine). |
| Man presents with severe muscle rigidity, high fever, and elevated CK levels following antipsychotic use. | Neuroleptic Malignant Syndrome (NMS) | This is a life-threatening emergency requiring immediate discontinuation of the offending agent and supportive care (cooling blankets, Dantrolene). |
| Patient believes classmates are conspiring to bring him down and sets up cameras in his apartment. | Paranoid Personality Disorder | Characterized by pervasive distrust and suspicion of others; this pattern fits better than delusional disorder because it is stable over time. |
| A patient who struggles with emotional regulation, intense fear of abandonment, and self-harming behaviors. | Borderline Personality Disorder (BPD) | These core features define BPD, often presenting in the context of relationship distress. |
| Patient has difficulty concentrating, poor appetite, and loss of interest over a year, but labs are normal. | Major Depressive Disorder/Apathy | The constellation of symptoms suggests chronic depressive or anhedonic state; ruling out organic causes (TSH/T4) is key. |
Differential diagnosis / distinguishing features
Obsessive-Compulsive Spectrum Differentiation
| Key Features | Distinguishing Findings | Next Step |
| Obsessive-Compulsive Disorder (OCD) | Thoughts/rituals are ego-dystonic (patient recognizes them as irrational). | Exposure and Response Prevention (ERP) therapy; SSR Is. |
| Obsessive-Compulsive Personality Disorder (OCPD) | Beliefs about orderliness, perfectionism, and control are ego-syntonic (feels necessary/right). | Psychotherapy focusing on flexibility and interpersonal boundaries. |
Movement Disorders Differentiation
| Key Features | Distinguishing Findings | Next Step |
| Acute Dystonia | Sudden, sustained muscle contractions; often triggered by medication. | Anticholinergics (e.g., benztropine) or benzodiazepines. |
| Akathisia | Constant feeling of inner restlessness/pacing urge. | Beta-blockers (Propranolol) are first line; Benzodiazepines. |
| Tardive Dyskinesia (TD) | Chronic, involuntary, repetitive movements (e.g., tongue, jaw). | Discontinue offending agent or switch to an atypical antipsychotic/Clozapine. |
Management pearls
- For acute psychosis in a patient with high suspicion of schizophrenia, start with an atypical neuroleptic unless contraindicated.
- When managing TD, the goal is not just symptom control but preventing irreversible damage; Clozapine remains critical for this indication.
- In suspected NMS, supportive care (cooling blankets) and immediate discontinuation of dopamine antagonists are paramount; do not wait for lab confirmation.
- For bipolar disorder management, Lithium requires careful monitoring due to its narrow therapeutic window and risk in renal failure.
Don't miss
🚨
Atypical vs. Typical: Atypicals block 5 HT2 A receptors, which increases DA release in the mesocortical pathway (helping negative symptoms).
🚨
Hyperprolactinemia Risk: Risperidone is the most notable agent for this side effect due to its strong D2 blockade in the tuberoinfundibular pathway.
🚨
Metabolic Monitoring: Any patient starting an antipsychotic must be monitored for weight gain, dyslipidemia, and elevated HbA1c (Olanzapine risk).
🚨
Diagnosis by Time: Always use symptom duration (< 1 mo vs 1-6 mo vs > 6 mo) to differentiate the primary psychotic disorders.
Integration & clinical reasoning
- The understanding of dopamine pathways (mesolimbic, mesocortical, nigrostriatal) is central to psychopharmacology and explains both positive/negative symptoms and EPS side effects.
- Personality disorder diagnosis requires careful history taking to distinguish between stable personality traits (P Ds) versus transient symptom clusters (e.g., during a manic episode).
Concept connections / cross-references
- No explicit cross-references.
High-yield association table
| Condition | Association | Mechanism | Clinical Significance |
| Schizophrenia | Positive Symptoms | Excess Dopamine in the Mesolimbic Pathway | Typical antipsychotics block D2 receptors, reducing positive symptoms but also causing EPS. |
| Schizophrenia | Negative Symptoms | Reduced Dopamine in the Mesocortical Pathway | Atypical agents help by blocking 5 HT2 A receptors, which indirectly increases DA release here. |
| Hyperprolactinemia | Risperidone/Haloperidol | D2 receptor blockade in the tuberoinfundibular pathway | Leads to decreased dopamine inhibition of prolactin release, causing elevated levels and subsequent side effects (galactorrhea, amenorrhea). |
| NMS | Dopamine Antagonism | High-dose antipsychotics block dopamine receptors centrally. | Requires immediate supportive care; discontinuation is mandatory. |
Key terms glossary
| Term | Definition | Context | Example |
| Positive Symptoms | Psychotic additions to normal functioning (e.g., hallucinations, delusions). | Schizophrenia diagnosis. | Hearing voices or believing one is being followed by the FBI. |
| Negative Symptoms | Deficits in normal emotional/cognitive function (e.g., flat affect, avolition). | Core feature of schizophrenia; often harder to treat than positive symptoms. | Social withdrawal or inability to initiate goal-directed activity. |
| Atypical Antipsychotic | Agents with a complex MOA, including 5-HT2 A antagonism. | Preferred first-line treatment for psychosis due to lower EPS risk. | Risperidone, Olanzapine, Aripiprazole. |
| Ego-syntonic | Behavior or belief that the individual perceives as normal and consistent with their self-image. | Used in OCPD; the patient does not feel they are acting abnormally. | Spending 15 hours a day meticulously handwriting notes because it feels necessary for success. |
Study optimization
| Topic | Study Approach | Priority | Resources |
| Psychopharmacology | Create flowcharts mapping drug -> MOA -> Side Effect. | High | Review the specific D2/5-HT receptor binding profiles for all major antipsychotics. |
| Differential Diagnosis | Use a structured approach (e.g., symptom duration, presence of mood symptoms) to rule in/out disorders. | Medium-High | Practice distinguishing between Schizophrenia, Schizotypal PD, and Schizoaffective Disorder using timeframes. |
| Personality Disorders | Focus on the quality of distress: Is it internal (OCD), relational (BPD), or pervasive distrust (Paranoid PD)? | Medium | Memorize the core features for Antisocial, Borderline, Narcissistic, and Avoidant P Ds. |
Question pattern recognition
- The "Best Next Step" Question: These questions test clinical judgment over rote memorization; always consider safety and efficacy.
- Symptom Cluster Recognition: Identifying which combination of symptoms (e.g., flat affect + delusions) points to a specific diagnosis is key.
- Pharmacology Association: Linking a drug's unique side effect (e.g., Risperidone -> Hyperprolactinemia) to its mechanism of action.
Test yourself
Common mistakes to avoid
🚫
Confusing the criteria for Schizophreniform Disorder (< 6 months) and Schizotypal PD (weird beliefs, no full psychosis).
🚫
Forgetting that OCPD is ego-syntonic —the patient feels normal about their need for order.
🚫
Assuming all antipsychotics cause TD; remember it's related to D2 blockade severity/duration.
Common traps
⚠️
The "Atypical" Trap: Do not assume an atypical agent is safe; always check the specific side effect profile (e.g., Olanzapine -> Metabolic Syndrome).
⚠️
The Timeframe Trap: Never diagnose Schizophrenia if symptoms are < 6 months; use the appropriate differential diagnosis instead.
⚠️
The MOA Trap: Remember that Aripiprazole is a partial agonist at DA receptors, not just an antagonist.
OMM / COMLEX integration
🦴
High-Yield Viscerosomatics, Autonomics & COMAT Shelf Clinical Pearls:
- Autonomic Nervous System Drug Targets: Systemic pharmacologic agents alter sympathetic and parasympathetic balance. Anticholinergic drugs (atropine, diphenhydramine) paralyze parasympathetic outflow from the vagus and pelvic splanchnics (urinary retention, ileus), while cholinergic agents (organophosphates, pyridostigmine) produce profound parasympathomimetic overactivation.
- Viscerosomatic Manifestations of Drug Toxicity: Drug-induced hepatotoxicity (acetaminophen, methotrexate) triggers acute tissue texture changes at right T5–T9 paraspinal tissues. Drug-induced interstitial nephritis (NSAIDs, penicillins) manifests at T10–L1.
- Detoxification & Lymphatics: Renal and hepatic clearance of pharmacologic metabolites is enhanced by maintaining thoracic inlet patency, ensuring unimpeded thoracic duct drainage into the left subclavian vein.